Research · Sep 3, 2026
[PODD] Insulet Thesis 2026: OmniPod 5 Enters Type 2 Expansion as International Reimbursement Ramps
Insulet's OmniPod 5 drove FY2025 revenue to ~$2.80B (+22%) with international markets leading at ~60-63% of revenue as European reimbursement for AID functionality expanded country by country. Gross margins hit ~69% on pod manufacturing efficiency. The FY2026 thesis: Type 2 insulin-dependent expansion (3M+ US patients, ~2-4% penetrated vs. ~30% Type 1 pediatric) extends OmniPod's growth duration well beyond Type 1 saturation — OmniPod 5's pharmacy distribution and no-tubing simplicity make it the first pump realistically adopted in primary care Type 2 settings.